Chemically Modified Adeno-associated Virus Capsid as a Promising Targeting Alternative for Gene Delivery – ChemAAV
*
*
*
The objective of this project mixing organic chemistry and virology is to develop Adeno-Associated Vectors (AAVs) chemically modified to improve its safety and efficacy. AAVs are now becoming therapeutic products, however, clinical trials showed critical limitations: high doses are required to achieve therapeutic efficacy and off-target tissue transduction. ChemAAV will allow optimal cell targeting with enhanced therapeutic index and restricted biodistribution. These improvements will be obtained by chemical coupling of a ligand with targeting properties at the surface of the AAV, exploiting natural amino-acids of the capsid. The advantage of chemistry is the possibility to modify the AAV capsid with synthetic polymers, peptides, carbohydrates or even lipids that cannot be incorporated genetically. The covalent coupling and thus the modification of tyrosine having been validated, we will focus on the evaluation of these particles on two target cells for the proof-of-concept studies; hepatocytes and hematopoietic stem cells, with direct applications for liver, blood disorders, and immunodeficiencies.
*
*
*
*
The objective of this project mixing organic chemistry and virology is to develop Adeno-Associated Vectors (AAVs) chemically modified to improve its safety and efficacy. AAVs are now becoming therapeutic products, however, clinical trials showed critical limitations: high doses are required to achieve therapeutic efficacy and off-target tissue transduction. ChemAAV will allow optimal cell targeting with enhanced therapeutic index and restricted biodistribution. These improvements will be obtained by chemical coupling of a ligand with targeting properties at the surface of the AAV, exploiting natural amino-acids of the capsid. The advantage of chemistry is the possibility to modify the AAV capsid with synthetic polymers, peptides, carbohydrates or even lipids that cannot be incorporated genetically. We will focus on two target cells for the proof-of-concept studies; hepatocytes and hematopoietic stem cells, with direct applications for liver, blood disorders, and immunodeficiencies.
Project coordination
Mathieu MEVEL (THERAPIE GENIQUE TRANSLATIONNELLE DES MALADIES GENETIQUES)
The author of this summary is the project coordinator, who is responsible for the content of this summary. The ANR declines any responsibility as for its contents.
Partnership
UMR_S1089 THERAPIE GENIQUE TRANSLATIONNELLE DES MALADIES GENETIQUES
CEISAM CHIMIE ET INTERDISCIPLINARITE : SYNTHESE, ANALYSE, MODELISATION
Physiologie des Adaptations Nutritionnelles
CIRI CENTRE INTERNATIONAL DE RECHERCHE EN INFECTIOLOGIE
Help of the ANR 479,671 euros
Beginning and duration of the scientific project:
September 2019
- 42 Months